|
Risk of acute leukemia and myelodysplastic syndromes in patients with monoclonal gammopathy of undetermined significance (MGUS): a population-based study of 17 315 patients
|
Feb 2013
|
Leukemia
|
myelodysplastic syndromes (MDS)
|
|
Risk for developing myelodysplastic syndromes in prostate cancer patients definitively treated with radiation
|
Mar 2014
|
J Natl Cancer Inst
|
myelodysplastic syndromes (MDS)
|
|
Risk factors for de novo and therapy-related myelodysplastic syndromes (MDS)
|
Jan 2021
|
Cancer Causes & Control : CCC
|
myelodysplastic syndromes (MDS)
|
|
Risk and timing of cardiovascular death among patients with myelodysplastic syndromes
|
Oct 2017
|
Blood Advances
|
myelodysplastic syndromes (MDS)
|
|
Rigosertib versus best supportive care for patients with high-risk myelodysplastic syndromes after failure of hypomethylating drugs (ONTIME): a randomised, controlled, phase 3 trial
|
Mar 2016
|
Lancet Oncol
|
myelodysplastic syndromes (MDS)
|
|
Rigosertib in Combination With Azacitidine in Patients With Myelodysplastic Syndromes or Acute Myeloid Leukemia: Results of a Phase 1 Study
|
Jul 2020
|
Leukemia Research
|
acute myeloid leukemia (AML), myelodysplastic syndromes (MDS)
|
|
Rewriting the rules for care of MDS and AML patients in the time of COVID-19
|
Apr 2020
|
Leukemia Research Reports
|
acute myeloid leukemia (AML), myelodysplastic syndromes (MDS)
|
|
Revisiting use of growth factors in myelodysplastic syndromes
|
May 2012
|
Asian Pac J Cancer Prev
|
myelodysplastic syndromes (MDS)
|
|
Revised International Prognostic Scoring System (IPSS-R) for myelodysplastic syndromes
|
Jun 2012
|
Blood
|
myelodysplastic syndromes (MDS)
|
|
Revised International Prognostic Scoring System (IPSS) Predicts Survival and Leukemic Evolution of Myelodysplastic Syndromes Significantly Better Than IPSS and WHO Prognostic Scoring System: Validation by the Gruppo Romano Mielodisplasie Italian Regional
|
Jun 2013
|
J Clin Oncol
|
myelodysplastic syndromes (MDS)
|
